14-day Premium Trial Subscription Try For FreeTry Free
FRA:BZ9
Delisted

Booz Allen Hamilton Holding Corporation Stock Signals

102.20€
+0 (+0%)
At Close: Dec 22, 2023

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 480 days ( -57.23 % )
Last Price 102.20€ 0 %
High/ Low 102.20€ - 102.20€ 0%
Chg 7 Days N/A $102.20 102.20€
Chg 30 Days N/A $102.20 102.20€
Chg 12 mos 3.80 % $98.46 102.20€
Trend - 3 mos 0.173 % Width: 1.02 %
Trend - 12 mos 20.31 % Width: 30.39 %
Pred. range - 3 mos 101.45€ - 102.49€ -0.732 % - 0.283 %
Pred. range - 12 mos 113.21€ - 147.61€ 10.77 % - 44.43 %
Short MA avg 3 mos Buy Sep 27, 2023 - 63 days
Long MA avg 3 mos Buy Nov 06, 2023 - 35 days
Short/Long MA avg 3 mos Buy Nov 06, 2023 - 35 days
Short MA avg 12 mos Buy Oct 17, 2023 - 49 days
Long MA avg 12 mos Sell Oct 06, 2023 - 56 days
Short/Long MA avg 12 mos Sell Oct 11, 2023 - 53 days
Pivot Short Buy Dec 21, 2023 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Booz Allen Hamilton Holding Corporation

Booz Allen Hamilton Holding Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine,... BZ9.F Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT